ArticleScientific reports2025
Lectin pathway components and autoantibodies as novel immunological biomarkers in systemic lupus erythematosus (SLE) patients from Western India.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mapping organ-associated autoantigenic landscapes in systemic lupus erythematosus.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The lectin pathway of complement aids in removing apoptotic cells and maintenance of tissue homeostasis. However, its role in SLE pathogenesis remains unknown. This study aimed to assess the association of ficolins, mannose-binding lectin (MBL), and other pathogen recognition molecules (PRMs) of the lectin pathway and their corresponding autoantibodies with various clinical manifestations and disease activity in SLE patients from Western India. In this cross-sectional study, 282 clinically diagnosed SLE patients were included. Serum levels of ficolins, antigenic MBL, MBL-associated serine proteases (MASPs), MBL-associated protein 44 (MAp44), Collectin liver-1 (CL-L1), and their corresponding autoantibodies were quantified using ELISA. Group differences were analyzed using Mann-Whitney U tests, while associations/relationships were evaluated using chi-square tests and Spearman's correlations. Serum levels of ficolin-2 (p < 0.001), MASP-3 (p = 0.030), and MAp44 (p < 0.001) were significantly elevated, while antigenic MBL (p < 0.001) and MASP-1 (p < 0.001) were significantly reduced in SLE patients compared to healthy controls (HCs). Renal involvement was associated with elevated ficolin-1 (p = 0.009), while hematological manifestations were linked to reduced MASP-1 (p = 0.018), MASP-3 (p = 0.002), and MAp44 (p = 0.002) levels. Mucocutaneous manifestations were associated with elevated MAp44 (p < 0.001) and anti-ficolin-1 (p = 0.038) autoantibodies. Anti-ficolin-1 (p = 0.001), anti-ficolin-2 (p = 0.001), and anti-ficolin-3 (p < 0.001) autoantibodies were significantly elevated in SLE patients compared to HCs. Anti-ficolin-2 autoantibodies were negatively correlated with ficolin-2 (r=-0.153, p = 0.015). Anti-MBL antibodies were correlated with SLEDAI (r = 0.169, p = 0.007) and anti-dsDNA antibodies (r = 0.178, p = 0.005). These findings indicate altered levels of lectin pathway-associated PRMs and their corresponding autoantibodies in SLE. Their association with clinical manifestations, disease activity, and complement-related parameters, suggest their potential as novel biomarkers in SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.